New, improved formulation set to replace EGRIFTA SV®
Comorbidities
March 27, 2025
MONTREAL, March 25, 2025 — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin for injection. The Company will commercialize the new formulation under the tradename EGRIFTA WRTM.
Tesamorelin for injection is the only medication approved in the U.S. for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy. The new formulation, EGRIFTA WRTM, is a daily injectable but only needs weekly reconstitution. It requires less than half the administration volume as the current F4 formulation, sold in the U.S. as EGRIFTA SV®, which is reconstituted daily. Pharmacokinetic studies have shown bioequivalence of EGRIFTA WRTM to the original F1 formulation of tesamorelin for injection (previously sold under the trade name EGRIFTA®). The most commonly reported adverse reactions of EGRIFTA WRTM include arthralgia, injection site reactions, pain in extremity, peripheral edema, and myalgia.
Read the full company press release here.
SEE ALSO:
Infectious Disease Special Edition: FDA approves EGRIFTA WR to treat excess visceral abdominal fat in adults with HIV Contagion Live: FDA approves F8 formulation of Theratechnologies’ tesamorelin for HIV-associated lipodystrophy Contagion Live: Clinical insights on HIV-associated visceral fat following FDA approval of tesamorelin F8 Contagion Live: The importance to address and help visceral adiposity in HIV patients
July 10, 2026
aidsmap: From ‘life span’ to ‘health span’ – new guidelines for ageing with HIV in South Africa
July 8, 2026
TheBodyPro: ‘An abject failure’: The case for tobacco harm reduction in HIV care
July 5, 2026
Cancer Health: HIV raises hepatitis C liver disease risk in women more than men
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Become a member Support us
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.
EATG Newsletter HIV&Co-infections Bulletin